BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Topiramate (Topamax) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Topiramate (Topamax)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05582837-8790@assetmemo.bio
DTSTAMP:20261121T005945Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Topiramate (Topamax): Phase 4 readout est. (NCT05582837)
DESCRIPTION:Topiramate (Topamax)\, phase 4\, Migraine.\nStudy: Treatment of
  Meniere's Disease With Migraine Medications\nEstimated primary completion
 : 30 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 opiramate-topamax#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05582837
URL:https://assetmemo.bio/drug/topiramate-topamax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06972056-8790@assetmemo.bio
DTSTAMP:20261121T005945Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Topiramate (Topamax): Phase 4 readout est. (NCT06972056)
DESCRIPTION:Topiramate (Topamax)\, phase 4\, Migraine.\nStudy: Comparative 
 Effectiveness of Migraine Preventive Medications: The APT Comparison Study
 \nEstimated primary completion: 1 March 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/topiramate-topamax#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06972056
URL:https://assetmemo.bio/drug/topiramate-topamax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
